Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GNI GroupGNIIF 86 3-1 Month Momentum % is N/A% as of Aug. 08, 2026. GuruFocus rates GNIIF with a GF Score™ of 86/100 and a GF Value™ of $17.97. The stock has 5 warning signs investors should review. Among 1,387 Biotechnology companies, GNI Group ranks better than 54.87% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-08), GNI Group's 3-1 Month Momentum % is N/A%.
The industry rank for GNI Group's 3-1 Month Momentum % or its related term are showing as below:
GNIIF's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -6.98 * Ranked among companies with meaningful 3-1 Month Momentum % only.
GNI Group (OTCPK:GNIIF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
GNI Group 3-1 Month Momentum % Related Terms
GNIIF vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, GNI Group's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GNI Group 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GNI Group's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where GNI Group's 3-1 Month Momentum % falls into.
GNI Group (OTCPK:GNIIF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNI Group (GNIIF) has a 3-1 Month Momentum % of N/A% as of Aug. 08, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on GNI Group and its competitors. According to the industry distribution chart, GNI Group ranks #626 out of 1387 companies in the Biotechnology industry, placing it in the top 45.1%.
Is GNI Group's 3-1 Month Momentum % too high?
GNI Group's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, GNI Group ranks #626 out of 1387 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GNI Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does GNI Group's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GNI Group ranks #626 out of 1387 companies for 3-1 Month Momentum %. This puts GNI Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on GNI Group and its competitors. GNI Group's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GNI Group stock overvalued right now?
GNI Group (GNIIF) has a current 3-1 Month Momentum % of N/A%. The stock's GF Value™ is $17.97, compared to a current price of $15.50 — trading 13.7% below its estimated fair value. The current 3-1 Month Momentum % is N/A%. GNI Group's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For GNI Group (GNIIF), the current 3-1 Month Momentum % is N/A% as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GNI Group (GNIIF) Overvalued in 2026?
Based on GuruFocus' analysis, GNI Group stock appears to be undervalued.
The current stock price of $15.50 is trading 13.7% below its estimated GF Value™ of $17.97.
Key valuation signals for GNIIF:
3-1 Month Momentum %: N/A%
GF Value™: $17.97 vs. price of $15.50 (13.7% below fair value)
No single metric tells the full story. See the GNIIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
86GF Score
Get the complete analysis for GNIIF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNIIF has been successfully added to your 
